Please login to the form below

Not currently logged in
Email:
Password:

Health Canada

This page shows the latest Health Canada news and features for those working in and with pharma, biotech and healthcare.

Distribution of Novartis’ generic Zantac halted due to carcinogen concerns

Distribution of Novartis’ generic Zantac halted due to carcinogen concerns

Other versions of Zantac have also been recalled in Europe and Canada as well. ... This includes Health Canada, who advised companies to halt manufacturing"until evidence is provided to demonstrate that they do not contain NDMA above acceptable

Latest news

  • The Final Frontier The Final Frontier

    Using Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR) database, there are about 350, 000 medical cannabis patients in Canada or 1% of the population (see Figure 1). ... Rohit Khanna is the Managing Director of Catalytic

  • Vertex calls NHS England ‘outrageous’ as Orkambi talks stall again Vertex calls NHS England ‘outrageous’ as Orkambi talks stall again

    Orkambi (ivacaftor/lumacaftor)  targets a mutation that around 50% of people with CF in the UK have, and has been shown to improve lung health and reduce hospitalisations. ... NHS England adds that it is not alone in being unable to make the drugs

  • EMA starts rapid review of Shire’s HAE antibody EMA starts rapid review of Shire’s HAE antibody

    Lanadelumab (SHP643) is also being assessed by Health Canada under a priority review application, and was submitted to the FDA last month.

  • Not in my backyard Not in my backyard

    And then after two years of doing this from Canada, the Secretary of Health and Human Services would have the authority to permit importation from countries in the Organisation for Economic ... And if 40% of US prescriptions flow through Canada, the

  • Sanofi/Regeneron bag first approval for Actemra rival sarilumab Sanofi/Regeneron bag first approval for Actemra rival sarilumab

    Competition to Roche’s blockbuster RA therapy heats up as Canada is first to licence new drug. ... Health Canada has given a green light to the interleukin-6 inhibitor - under the Kevzara brand name - for the treatment of moderately to severely active

More from news
Approximately 2 fully matching, plus 37 partially matching documents found.

Latest Intelligence

  • Gathering pace: adaptive pathways Gathering pace: adaptive pathways

    Canada has also been developing the concept under the banner of 'progressive licensing'. ... and Finn Børlum-Kristensen from the European network for health technology assessment and Danish Health and Medicines Authority.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics